Tag Archives: panel

RESI@TMCx Panel Announcement: Venture Philanthropy Investors

10 Mar

By Christine A. Wu, Research Analyst, LSN

chrsitine

Venture philanthropy organizations provide more than just financing. Often times, these investors can provide a network of experts, patients, and resources in their niche space. Here in Next Phase, LSN has previously covered trends in venture philanthropy investment and advice in how to approach venture philanthropy investors.

LSN is pleased to announce a panel of five investors in the venture philanthropy space for RESI@TMCx on April 11th. Moderated by Jit Patel, VP of Research and Business Development of Juvenile Diabetes Research Foundation (JDRF), the panel will be joined by:

Panelists will address their specific investment criteria and unique missions; their investment decision-making process; important trends in the space; and the best approach to reach and heighten their interest.

Interested in this panel? It’s not too late to register for RESI@TMCx Houston and see this panel live. View the full RESI@TMCx agenda here. You can also view a video recap of our RESI San Francisco Venture Philanthropy session.

RESI-Houston-2016_600

Tags: , , , , , ,

Redefining Early Stage Investments (RESI) Conference: Corporate VCs & Strategic Investment Panel

7 Jan

By Christine A. Wu, Research Analyst, LSN

chrsitine

At LSN’s RESI San Francisco Conference next Tuesday, January 12th, the Corporate VC & Strategic Investment panel will focus on how major pharmaceutical companies evaluate and invest in early stage life science companies, both through corporate venture capital arms and internal investment units.

In this panel, corporate VC and major pharmaceutical investors will discuss the types of companies they’re interested in investing in, and how they structure these opportunities to achieve their strategic aims. Panelists will provide advice on how entrepreneurs can engage with a corporate investor, and what to expect from an investment relationship with a large pharmaceutical company.

Moderated by Edward Hu, CFO & CIO of WuXi AppTec, the audience will hear from:

  • Carolyn E. Green, Executive Director, Strategic Investments, Worldwide R&D, Pfizer
  • Geeta Vemuri, Vice President, Head, Baxalta Ventures
  • Hakan Goker, Senior Investment Director, MS Ventures
  • Ilan Zipkin, Senior Investment Director, Takeda Ventures

If you’re a fundraising entrepreneur seeking strategic investments with a major pharmaceutical company, this panel is not one you want to miss. RESI San Francisco is already the largest RESI yet with over 700 attendees. This will be a great opportunity to expand your network in the life science space, so register now before it’s too late.

RESI-San-Francisco-2016

Tags: , , , , ,

Redefining Early Stage Investments (RESI) Conference: Healthcare IT Investors Panel

17 Dec

By Shaoyu Chang, MD, MPH,  Senior Research Manager, LSN

Shaoyu 10*10

At the intersection between life science and computer science, healthcare IT continues to attract strong interests from both camps. VC funds, big pharmas, and tech corporates are all actively seeking the next big thing in HCIT that would transform healthcare fundamentally.

Some of the biggest players in HCIT investment will speak at RESI San Francisco to share their expertise and advice with entrepreneurs. Moderated by Anne DeGheest, Founder of HealthTech Capital, the panel will feature:

This panel will provide fundraising entrepreneurs with an inside peak into the strategy of these HCIT investors – How do you make your company stand out in this crowded marketplace? What do investors see as the most high-potential fields of innovation in healthcare IT? How do you demonstrate to an investor that your product has the potential to succeed?

If you’re interested in listening to this panel live at RESI, you can register for RESI San Francisco now. RESI provides a great opportunity to expand your network in the life sciences and to get a better understanding of fundraising process, and January 12th will be our largest gathering yet.

RESI-San-Francisco-2016

Tags: , , , , , ,

Redefining Early Stage Investments (RESI) Conference: Orphan & Rare Disease Investors Panel

10 Dec

By Christine A. Wu, Research Analyst, LSN

chrsitine

The orphan and rare disease space has gained significant traction among life science investors. Despite the smaller market populations and limited clinical trial participants in rare diseases, technology in this space has remained attractive to investors due to its expedited FDA process and its lack of current treatment options for such uncommon conditions. Overall, while there are many challenges, there remains a lot of hope to drastically impact patient populations, scientific advancement, and market potential.

RESI San Francisco will bring together well-established investors in the rare and orphan disease space on January 12th. Moderated by Mark Day, Executive Director and Head of External Research & Scouting of Alexion Pharmaceuticals, panelists will include:

Panelists will discuss the attractiveness of orphan and rare disease technologies in comparison to non-orphan opportunities; what the rare disease spaces offers to investors; the best way to position an orphan opportunity to a potential investor; the evaluation process in assessing products in the space; as well as common trends, challenges, and excitement in the scientific advancement of the field.

To all the hopefuls in the orphan and rare disease space, this panel is for you. Register for RESI San Francisco now to hear this panel live – partnering has already begun and this event will be LSN’s biggest RESI yet.

RESI-San-Francisco-2016

Tags: , , , ,

RESI Panel Announcement: Diagnostic Investors

3 Dec

By Nicholas Civitarese, Research Analyst, LSN

nick-wp

The amount of capital being invested in medical technology and diagnostics is at its highest point since 2008. However, companies in the diagnostics space face some unique challenges in the fundraising landscape.

To inform your fundraising campaign’s direction, Life Science Nation is pleased to announce a panel of six investors with expertise in the diagnostics space for RESI San Francisco on January 12th. Moderated by Akhil Saklecha, Partner at Artiman Ventures, the panel will feature:

This panel will provide fundraising entrepreneurs with an inside peak into the strategy of these diagnostic investors – including best practices for building relationships with diagnostic investors as well as advice on making sure your diagnostic company is positioned as a strong investment opportunity.

If you’re interested in listening to this panel live at RESI, you can register for RESI San Francisco now. RESI provides a great opportunity to expand your network in the life sciences and to get a better understanding of fundraising process, and January 12th will be our largest gathering yet.

RESI-San-Francisco-2016

Tags: , , , , , , ,

RESI SF Panel Annoucement: Big Pharma

25 Nov

By Lucy Parkinson, Director of Research, LSN

One of the key shifts in the life science product development landscape in recent years is that big pharma companies are increasingly looking outward for innovation. Pharma corporate development groups are deploying an array of means to source, evaluate and invest in assets discovered or developed by biotech entrepreneurs.

At RESI San Francisco, the Big Pharma panel will explore the shifting dynamic between big pharma and small biotechs. What can you expect from a pharma company’s evaluation process, and what can you do to position your startup to make a deal?  Panelists will answer these questions and provide their advice on how entrepeneurs can take align themselves with the firms that they represent.

Moderated by Kevin Lynch, Vice President, Scientific Assessment, AbbVie, the panelists are:

If you’d like to hear this panel live at RESI and meet with investors from the pharma world and beyond, you can register for RESI San Francisco now.

RESI-San-Francisco-2016

Tags: , , , , , ,

Panel Announcement: Venture Philanthropy Investors

19 Nov

By Christine A. Wu, Research Analyst, LSN

chrsitine

Venture philanthropy has been a vital source of capital for early stage life science companies over the years. Philanthropic organizations provide more than just financing; a foundation with a niche indication focus may supply a network of experts, patients, and resources in the field. These organizations have an underlying mission to improve specific patient outcomes, going as far as using their financial returns toward further initiatives and investments to achieve their mission. Due to these organizations’ unique missions, LSN has uncovered a number of investment trends and accumulated advice in how to approach venture philanthropy investors.

LSN is pleased to announce a panel of five expert representatives in the venture philanthropy space for the RESI San Francisco Conference on January 12th. Moderated by Chris de Souza, Director of Broadview Ventures, the panel will be joined by:

Panelists will address their specific investment criteria and unique missions; their particular investment decision-making process; the relevant questions to ask and the best approach to reach and heighten their interest; along with important trends to keep in mind.

If venture philanthropy investment is part of your plan to get your company funded, this panel is a fantastic opportunity to extend your network and expand your understanding of these organizations.

RESI-San-Francisco-2016

Tags: , , , , ,

← Older Entries
Newer Entries →